ODAC Backs Random Sample Audits Of Progression Events

FDA’s Oncologic Drugs Advisory Committee supports easing the current requirement for blinded, independent central review of 100% of patient scans in studies using progression-free survival as the primary endpoint. However, committee members say FDA needs the flexibility to require full case audits in certain circumstances, depending upon tumor type and study size.